LGD-4033 Overview
LGD-4033 (Ligandrol) is a non-steroidal selective androgen receptor modulator developed for research applications investigating anabolic pathways. This compound binds selectively to androgen receptors in muscle and bone tissue with high binding affinity, demonstrating tissue-selective androgenic activity in preclinical models. Researchers evaluate Stroid UK Shop for its potential in muscle-wasting studies and osteoporosis research, having advanced through Phase I clinical trials with documented oral bioavailability. The compound’s selective mechanism offers researchers a valuable tool for examining androgen receptor signalling without the broader androgenic effects observed with traditional compounds.
Laboratory Research Applications
Scientists study LGD-4033 in multiple research contexts, particularly examining its effects on muscle protein synthesis and bone density parameters. Research institutions investigate this compound’s anabolic activity in muscle tissue while noting reduced androgenic effects on prostate tissue in preclinical models. The selective nature allows researchers to examine specific pathways within the androgen receptor system. Studies focus on muscle-wasting conditions, sarcopenia models, and osteoporosis research applications. Scientists analyse cellular mechanisms including protein synthesis modulation and myofibrillar protein expression. Comparative studies with other SARM compounds help researchers understand tissue selectivity variations. The compound’s oral bioavailability makes it suitable for various experimental protocols requiring consistent dosing parameters in laboratory settings.
Technical Specifications
| Parameter | Specification |
|---|---|
| CAS Number | 1165910-22-4 |
| Molecular Formula | C₁₄H₁₂F₆N₂O |
| Molecular Weight | 338.25 g/mol |
| Classification | Non-steroidal SARM |
| Storage | Room temperature, protected from moisture |
| Manufacturer | Driada Medical |
Researchers studying metabolic pathways may also examine related compounds including peptide modulators for comprehensive pathway analysis. LGD-4033’s documented pharmacological profile provides researchers with established baseline data for experimental design and comparative studies.
Research Compliance Information
This LGD-4033 preparation from Driada Medical is intended exclusively for in-vitro laboratory research purposes. The compound is not approved for human consumption, therapeutic use, or any clinical applications. Researchers must handle this material according to appropriate laboratory safety protocols and institutional guidelines. All studies should comply with relevant research ethics standards and regulatory requirements for experimental compounds.
